Because electronic cigarettes (e-cigs) containing nicotine may relieve smoking abstinence symptoms similar to nicotine replacement therapy medication, we used within-subjects designs to test these effects with a first-generation e-cig in nonquitting and quitting smokers. In Study 1, 28 nontreatment-seeking smokers abstained overnight prior to each of 3 sessions. Minnesota Nicotine Withdrawal Scale (MNWS) withdrawal (and craving item) relief was assessed following 4 exposures (each 10 puffs) over 2 hr to e-cigs that either did (36 mg/ml) or did not (i.e., placebo, 0 mg/ml) contain nicotine or after no e-cig. Relief was greater after nicotine versus placebo e-cig (p Ͻ .05) but not after placebo versus no e-cig, showing relief was due to nicotine per se and not simple e-cig use behavior. Using a crossover design in Study 2, smokers preparing to quit soon engaged in 2 experimental 4-day quit periods on separate weeks. In weeks 1 and 3, all received a nicotine or placebo e-cig on Monday to use ad libitum while trying to abstain from smoking on Tuesday through Friday. (Week 2 involved resumption of ad libitum smoking.) MNWS and Questionnaire of Smoking Urges (QSU) craving were assessed at daily visits following 24-hr abstinence. Of 17 enrolled, 12 quit for Ն24 hr at least once, allowing test of relief because of e-cig use on quit days. Withdrawal and craving were reduced because of nicotine versus placebo e-cig use (both p Ͻ .05). In sum, compared with placebo e-cigs, nicotine e-cigs can relieve smoking abstinence symptoms, perhaps in a manner similar to Food and Drug Administration-approved nicotine replacement therapy products, although much more research with larger samples is needed.
Relevant to addressing the clinical utility of electronic cigarettes (e-cigarettes) in smoking cessation are their effects on abstinence symptom relief, which is an active focus of developing novel treatments for drug dependence (O'Brien, 2005) . Although not approved by the Food and Drug Administration (FDA) for use to quit smoking, e-cigarettes containing nicotine may be able to relieve symptoms of tobacco abstinence in a manner similar to that of FDA-approved nicotine replacement therapy (NRT; e.g., Beard, West, Michie, & Brown, 2016; . Very few formal cessation trials with e-cigarettes have been conducted (see recent reviews by Malas et al., 2016; Hartman-Boyce et al., 2016) , but some studies suggest their nicotine content may not be essential because placebo or nicotine e-cigarette use can similarly aid reduction in tobacco cigarettes per day among those not attempting to quit (Tseng et al., 2016) .
Notably, controlled studies suggest very short-term exposure to e-cigarettes may reduce withdrawal and craving after brief smoking abstinence, at least in the minutes after its use and in some smokers (e.g., Dawkins, Turner, Hasna, & Soar, 2012; Malas et al., 2016; Vansickel & Eissenberg, 2013 ). Yet whether even these brief abstinence relief effects are due specifically to nicotine from the e-cigarette may not be certain (Meier et al., 2017) because nicotine delivery from early versions may have been insufficient to demonstrate symptom relief (Etter, 2015; Farsalinos et al., 2014;  see also . Moreover, although some studies showing e-cigarettes with nicotine, compared with placebo, acutely reduce craving, each was used in ad libitum fashion over a brief period, allowing uncontrolled exposure (e.g., Dawkins, Turner, & Crowe, 2013) . Thus, any e-cigarette use may be effective, whether or not it contains nicotine, if simple vaping behavior is sufficient (Meier et al., 2017) . Also unclear is whether nicotine e-cigarettes can sustain relief from abstinence symptoms in smokers quit for at least 24 hr, as in a true quit attempt, rather than during the temporary abstinence in nonquitters typical of these acute tests.
To help understand the influence of nicotine intake per se via e-cigarettes for possible efficacy in relieving withdrawal and craving during smoking abstinence, we compared changes in symptoms because of controlled use of a first-generation nicotine versus a no-nicotine (placebo) e-cigarette (and vs. no e-cigarette use in Study 1). We used within-subjects designs to test these e-cigarettes on relief of symptoms in the following: (a) smokers not planning to quit permanently but were smoking abstinent overnight (Study 1), and (b) smokers already planning to quit permanently who were smoking abstinent at least 24 hr during at least one e-cigarette condition (Study 2). Both studies allowed comparison of symptom relief because of nicotine alone from the e-cigarette use (e.g., Cleophas, 1993) , simulating effects when using them for temporary relief (Study 1) or for initiating an attempt to quit smoking (Study 2).
Study 1

Method
Participants. Minimum eligibility was age 18 years or older with a smoking history of at least 10 cigarettes/day for Ͼ1 year, presence of Diagnostic and statistical manual of mental disorders (4th ed.) criteria for nicotine dependence (American Psychiatric Association, 1994) , and no interest in quitting in the next 6 months but also e-cigarette use no more than once/week. The 28 participants in Study 1 (12 men, 16 women) smoked a mean (ϮSD) of 15.7 Ϯ 5.2 cigarettes/day, with 1.1 Ϯ 0.1 mg nicotine yield of preferred brand (n ϭ 9 for menthol, 19 for nonmenthol). Age was 26.5 Ϯ 6.6 years, and men and women did not differ on these characteristics. They self-identified mostly as Caucasian (75.0%), with 21.4% African American and 3.6% more than one ethnicity. None had current or past history of weekly e-cigarette use, and none had used within the prior 2 weeks of participating.
Electronic cigarettes. These first-generation e-cigarettes were obtained from PrimeVapor LLC (Pleasant Prairie WI), labeled as containing 36 mg or 0 mg nicotine content per milliliter of liquid in 100% vegetable glycerin in prefilled cartridges (each with e-liquid weights of exactly 1 mg; www.primevapor.com). E-cigarettes have been shown to increase plasma nicotine levels after abstinence in a manner related to these liquid concentrations of 0 and 36 mg/ml, with levels of 3.8 ng/ml (no change from abstinent baseline) versus 17.0 ng/ml, respectively, following 10 puffs on each e-cigarette by 16 naïve users (see Lopez et al., 2016 ). Yet we did not obtain independent verification of nicotine delivery from ours, such as by testing the concentrations in e-liquid or in intermittent plasma samples from participants. The nicotine and placebo versions we used, Rawhide Red (tobacco) for nonmenthol and Freeport (menthol) for menthol, were those showing nicotine's acute reinforcement-enhancing effects (Perkins, Karelitz, & Michael, 2015) . We also selected them to closely match typical tobacco flavorings, given the lack of experience with e-cigarettes and unfamiliarity with other flavors in these participants. They were provided with a KR808D-1-type automatic e-cigarette battery (650 mAh battery life, constant 3.7 V, and 2.2 Ohm resistance) from Prime Vapor.
Procedure. This research was approved by the University of Pittsburgh Institutional Review Board. Three experimental sessions, each following overnight abstinence (verified by Vitalograph BreathCO, CO Յ10 ppm; SRNT Subcommittee on Biochemical Verification, 2002) , differed only in the administered e-cigarette condition: nicotine (36 mg) or placebo (0 mg) e-cigarettes (under blind conditions) or no e-cigarette. E-cigarette content was matched on menthol of the participant's preferred tobacco brand, given the stability of menthol preference (Kasza et al., 2014) and its influence on self-report ratings of these products (e.g., Audrain-McGovern, Strasser, & Wileyto, 2016; Strasser et al., 2013) . The purpose was to compare withdrawal relief effects of nicotine versus placebo e-cigarettes versus no e-cigarette, each after overnight abstinence. The order of these e-cigarette conditions across sessions was counterbalanced between subjects.
Participants completed the CO check to confirm abstinence and the Minnesota Nicotine Withdrawal Scale (MNWS) nicotine withdrawal measure (Hughes, 2007) upon arrival to each session. The MNWS items were each scored on 0 -100 visual analog scales, anchored by not at al" and extremely (as in . Although questionnaire of smoking urges (QSU)-brief craving (Cox, Tiffany, & Christen, 2001) was not obtained in Study 1 (but see Study 2), we assessed craving via the single Desire or Craving to Smoke item from the MNWS (i.e., Craving item). All rested quietly while reading and either did, or did not (no e-cigarette session), self-administer the designated e-cigarette as described below on four occasions per session, 25 min apart. The MNWS withdrawal measure was again assessed at the end of each 2-hr session to gauge differences in relief because of intermittent puffs on the nicotine and placebo e-cigarettes, compared with no e-cigarette use. Participants were compensated $20/hr for completing the entire study.
During the two e-cigarette sessions, subjects self-administered 10 puffs over 5 min from the designated e-cigarette, one puff every 30 s, as in other studies of acute e-cigarette effects (e.g., Dawkins & Corcoran, 2014; Lopez et al., 2016; Spindle et al., 2015; Vansickel & Eissenberg, 2013) . Similar to prior research standardizing tobacco cigarette topography (Perkins, Karelitz, Giedgowd, & Conklin, 2012) , the specific timing and duration of each puff inhalation by participants were guided by computer-displayed instructions, with a 4-s puff hold duration. To assess topography and confirm equal exposure between the e-cigarettes, all puffs were via a portable Clinical Research Support System (CReSS Pocket), with an adapter for use with e-cigarettes (E-Cig Adaptor 9.00 mm) obtained from Borgwaldt KC, Inc. (Richmond, VA).
Data Analyses. A one-way, repeated-measures analysis of variance, conducted using SPSS 24.0, tested the change in MNWS withdrawal score between time points (i.e., arrival baseline and end of session) as a function of the within-subjects independent variable e-cigarette condition (nicotine, placebo, no e-cigarette). Follow-up a priori pairwise comparisons compared the change from baseline beThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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tween the nicotine versus placebo e-cigarette conditions (isolating acute nicotine effects alone), the placebo e-cigarette versus no e-cigarette conditions (isolating effects of e-cigarette use behavior alone), and the nicotine e-cigarette versus no e-cigarette conditions (testing combined effects of acute nicotine and e-cigarette use behavior). We also conducted the same analyses just on responses to the single Craving item from the MNWS (Hughes, 2007) to assess effects on craving (again, because we did not obtain the QSU-brief in Study 1). A paired t test was conducted to verify no differences in puff topography responses to each e-cigarette condition (nicotine vs. placebo). No differences were significant because of the order of the e-cigarette conditions across sessions, so responses were collapsed across order. Cohen's d and partial eta-squared values ( p 2 ), were computed as measures of effect size for analyses of abstinence symptom relief (Cohen, 1988) .
Results
In preliminary comparisons, mean (ϮSEM) puff volume was not different between the nicotine versus placebo e-cigarette, 102.5 (Ϯ7.6) versus 110.8 (Ϯ6.6) ml/puff, respectively, t(27) ϭ 1.13, p Ͼ .25, d ϭ 0.21. When examining withdrawal change scores, primary analyses found a significant main effect of e-cigarette condition, F(2, 54) ϭ 6.92, p Ͻ .005, p 2 ϭ .20. As shown in Figure 1 , follow-ups indicated the decline in withdrawal was significantly greater during the nicotine e-cigarette condition when compared with no e-cigarette, t(27) ϭ 3.57, p Ͻ .005, d ϭ 0.68, and with the placebo e-cigarette condition, t(27) ϭ 2.17, p Ͻ .05, d ϭ 0.41. There was no significant difference in withdrawal relief between the placebo and no e-cigarette conditions, t(27) ϭ 1.50, p ϭ .14, d ϭ 0.28. Perhaps not surprisingly, virtually identical results were seen for the change from baseline on the single MNWS craving item, with a significant main effect of e-cigarette condition, F(2, 54) ϭ 4.38, p Ͻ .05, p 2 ϭ .14. A significantly greater reduction in craving was found for the nicotine e-cigarette condition versus no e-cigarette, t(27) ϭ 3.08, p ϭ .005, d ϭ 0.58, and versus placebo, t(27) ϭ 2.17, p Ͻ .05, d ϭ 0.41, with no difference between the placebo and no e-cigarette conditions, t(27) ϭ 0.65, p Ͼ .50, d ϭ 0.12.
In sum, e-cigarettes with nicotine, but not simple use of one without nicotine, relieved withdrawal (including the MNWS item on craving) during exposures after overnight abstinence in smokers not preparing to quit. Study 2 aimed to explore these effects during separate 4-day periods of ad libitum nicotine versus placebo e-cigarette exposure after Ն24 hr abstinence in those who were preparing to quit soon. (A third period involving quit days with no e-cigarette use, as in Study 1, was not feasible.)
Study 2 Method
Participants. Eligible for Study 2 were adult dependent smokers who did intend to quit tobacco permanently within the next 2 months (in contrast to those in Study 1). Those currently taking medications to treat serious psychological problems (e.g., psychosis, major depression) were excluded. Recruitment procedures were similar to those described in our earlier comparable crossover study on abstinence relief effects of week-long use of active NRT versus placebo patch . Of the 17 who enrolled, 12 (seven males, five females) were able to quit for at least 24 hr during one of the testing weeks so that symptom relief on quit days because of the e-cigarette's nicotine content could be compared. Mean (SD) characteristics of these 12 participants were 29.4 (11.3) years of age, self-report of smoking an average of 11.8 (2.3) cigarettes/day, 1.0 Ϯ 0.2 mg nicotine yield of preferred brand (n ϭ 8 for menthol, n ϭ 4 for nonmenthol), with seven identifying as Caucasian, four as African American, and one as Asian. As in Study 1, none had current or past history of regular e-cigarette use (mean Ϯ SD of 7 Ϯ 9 months since last use in the six who reported any prior exposure). Participants were compensated by $15/visit over 10 visits (see the Procedure section), plus the offer of 8 weeks of NRT patch treatment and brief cessation counseling to make a permanent quit attempt after the end of this study, all at no cost. (An offer of poststudy cessation treatment was a component of compensation specifically intended to attract those smokers already planning to quit soon.)
Procedure. This study was described to participants as not a treatment study but as a test of the effects of ad libitum use of two different e-cigarettes that may or may not contain nicotine while trying to quit tobacco use during week-long periods. Exactly the same nicotine versus placebo e-cigarettes described in Study 1 were used in Study 2, but use was ad libitum over days in Study 2 (rather than under tightly controlled conditions over 2-hr sessions in Study 1). To maximize statistical power (Cleophas, 1993) , we used a crossover design similar to our prior within-subject This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
comparison of symptom relief during cessation because of nicotine versus placebo patch . Thus, participants engaged in two separate 4-day quit attempt periods while using e-cigarettes that either did (36 mg/ml) or did not (i.e., placebo, 0 mg/ml) contain nicotine. During their 3 weeks of study participation, all were given their designated nicotine or placebo e-cigarette on Monday of weeks 1 and 3 and instructed to try and quit tobacco on Tuesday through Friday. Order of the e-cigarette conditions between weeks 1 and 3 was counterbalanced, and each was provided without identifying labels (i.e., blind). Week 2 involved resumption of ad libitum tobacco smoking (i.e., washout) and no study visits to equate prior smoking intake before both periods of using an e-cigarette while attempting to quit tobacco. Assessed at daily visits in weeks 1 and 3 were expired-air CO and measures of withdrawal (MNWS) and craving (QSU-brief; Cox et al., 2001) , both using items scored on 0 -100 visual analog scales, following 24-hr tobacco smoking abstinence (verified by Vitalograph BreathCO CO Ͻ5 ppm; Perkins, Karelitz, & Jao, 2013) . Abstinence Ն24 hr was required here so that symptom relief responses to ad libitum e-cigarette use when trying to quit tobacco would not be confounded by any recent smoking exposure. Amount of use was also assessed daily by subtracting the cartridge weight from that on the prior day. Participants received two new cartridges on the first day of each period. Empty cartridges were exchanged for new cartridges at each daily visit, as needed. To aid smoking cessation initiation during each brief quit period, all were given written suggestions on avoiding tobacco products, how to cope with urges, and so forth (adapted from Perkins, Conklin, & Levine, 2008) . They were also offered additional payment of $15 per quit day as motivation to abstain for Ͼ24 hr, beyond the daily compensation for study participation (noted above). This study was approved by the University of Pittsburgh Institutional Review Board.
Data Analyses. Multilevel modeling was performed using the MIXED command in SPSS 24.0 (Raudenbush & Bryk, 2001; Singer & Willett, 2003) . For Study 2, lower-level, withincondition days (Level 1) were nested within higher-level nicotine conditions (Level 2). Following best-practice recommendations (Aguinis, Gottfredson, & Culpepper, 2013) , two models were estimated per dependent variable: (a) a null model estimated without predictors from either level and (b) a random intercept and fixed-slope model. An intraclass correlation coefficient was computed using parameters estimated in Model 1 to quantify the proportion of total variance in each dependent variable because of the nicotine condition. Model 2 assessed differences between the nicotine versus placebo e-cigarette conditions on responding to each symptom measure, controlling for effects of Level 1 day. Means for each dependent variable by nicotine condition were estimated controlling for the effect of quit week day. Symptom data were included only for days in which 24-hr abstinence from tobacco smoking was verified (CO Ͻ5 ppm). No differences were found for the order of e-cigarette conditions between quit weeks 1 versus 3 in preliminary analyses.
Results
For the 12 participants able to quit Ն24 hr at least once during e-cigarette conditions, the number of days quit (mean Ϯ SEM), controlling for effect of day, did not differ due to nicotine versus placebo (2.9 Ϯ 0.3 vs. 2.3 Ϯ 0.3, respectively), t(82) ϭ 1.6, ns. Similarly, in preliminary comparisons, daily amount of ad libitum use of each e-cigarette cartridge was not different for nicotine versus placebo, 0.25 Ϯ 0.05 versus 0.30 Ϯ 0.05 mg, t(81.1) ϭ 1.1, ns (or about 25-30% each day of the 1-mg e-liquid per cartridge; www.primevapor.com). Therefore, the amount of exposure to each e-cigarette across quit days was similar, allowing controlled comparison of ad libitum nicotine versus placebo e-cigarette use on ability to attenuate abstinence symptoms.
Shown in Figure 2 are MNWS withdrawal and QSU craving by the nicotine and placebo e-cigarette conditions, controlling for the effect of day within condition. The intraclass correlation coefficients (calculated using parameters estimated in each symptom's respective Model 1) indicated 37% of variation in MNWS withdrawal and 62% of variation in QSU craving each were due to nicotine condition. Mean MNWS withdrawal, controlling for the effect of day, was lower in the nicotine versus placebo e-cigarette condition (23.0 vs. 31.3; t[53.1] ϭ 2.2, p Ͻ .05; difference of Ϫ8.3 Ϯ 3.8), as was QSU craving (28.4 vs. 35.6; t[51.0] ϭ 2.2, p Ͻ .05; difference of Ϫ7.1 Ϯ 3.3). In follow-ups of the QSU factor scores controlling for the effect of day, QSU factor 1 (reflecting positive smoking reward anticipation) was significantly decreased by nicotine versus placebo e-cigarette (34.2 vs. 43.3; t[50.9] ϭ 2.4, p Ͻ .05; difference of Ϫ9.1 Ϯ 3.8), but QSU factor 2 (anticipation of negative affect relief) was not significantly decreased (21.7 vs. 26.7; t[51.4 ] ϭ 1.6, p Ͼ .10; difference of Ϫ5.0 Ϯ 3.2).
Discussion
These results indicate that, compared with the use of placebo e-cigarettes, use of nicotine-containing e-cigarettes may be more Figure 2 . Mean Ϯ SEM MNWS withdrawal and QSU craving, controlling for effect of day, because of ad libitum use of nicotine versus placebo e-cigarette following Ͼ24 hr smoking abstinence (CO Ͻ5 ppm; N ϭ 12). ‫ء‬ p Ͻ .05 for relief because of the nicotine versus placebo e-cigarette. This document is copyrighted by the American Psychological Association or one of its allied publishers.
effective in reducing some tobacco abstinence symptoms, under controlled short-term conditions when not trying to quit smoking (Study 1) or under ad libitum use after Ն24 hr quit (Study 2). Specific comparisons in Study 1 showed relief was due to nicotine per se, as use of placebo e-cigarettes versus the no use condition was ineffective in relieving MNWS withdrawal (including the Craving item), suggesting no influence of simple e-cigarette use behavior. Very similarly, in Study 2 MNWS withdrawal and QSU craving, especially factor 1, were relieved by the nicotine versus placebo e-cigarette. Far more study is needed on e-cigarette efficacy in relieving craving and withdrawal during periods of Ͼ24 hr abstinence, but our findings suggest the potential for nicotine e-cigarettes to alleviate abstinence symptoms in a manner similar to that because of FDA-approved nicotine replacement treatments (e.g., Jorenby, Keehn, & Fiore, 1995) . Study 1 strengths include carefully controlled exposure to nicotine versus placebo e-cigarettes and the novel comparison of placebo versus a no e-cigarette condition to test simple behavioral effects of e-cigarette use. No effect of e-cigarette use without acute nicotine intake in Study 1 perhaps helps to address some of the uncertainty about the importance of nicotine intake from e-cigarettes in prior studies (cited in the introduction). We also documented comparable use of both e-cigarettes in Study 2 via daily change in cartridge weight, ruling out greater use of the nicotine versus placebo e-cigarette as a contribution to the difference in craving response. Yet lack of verification of the nicotine delivery here is a limitation in both studies, as is uncertainty about other potential constituents in the e-liquid. Despite the further limitation of a small abstinent sample in Study 2, that study used a stringent criterion of CO Ͻ5 ppm to biochemically verify 24-hr smoking abstinence every day during each period, allowing for careful comparison of symptom relief from nicotine versus placebo e-cigarette use during complete smoking abstinence. Finally, use of a within-subject design in both studies clearly isolated the influence of nicotine intake alone from e-cigarette use while maximizing the statistical power provided by small samples (Cleophas, 1993) .
In sum, our studies show relief because of nicotine in e-cigarette use, both during temporary abstinence in nonquitting smokers (Study 1) as well as during Ͼ24 hr abstinence in smokers planning to quit permanently (Study 2). Nevertheless, substantially more controlled research is needed on the effects of nicotine from e-cigarette use in relieving abstinence symptoms, with larger and diverse study samples assessed over longer durations of tobacco cessation. Because abstinence symptom relief only partly aids the ability to quit tobacco (e.g., Kenford et al., 1994) , long-term testing of nicotine e-cigarettes on success of continuous abstinence from smoking is needed to more fully determine their potential clinical efficacy (Malas et al., 2016) .
